XT
NVCT icon

XTX Topco’s Nuvectis Pharma NVCT Stock Holding History

XTX Topco’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$77.8K Buy
+10,066
New +$86.2K ﹤0.01% 3182
2025
Q4 		– Sell
-14,866
Closed -$89.5K – 3646
2025
Q3 		$89.5K Buy
+14,866
New +$102K ﹤0.01% 2047

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

XTX Topco's NVCT Position: Q1 2026 in Review

XTX Topco opened a new position in Nuvectis Pharma (NVCT) in Q1 2026: 10,066 shares worth $77.8K. The stake represents ﹤0.01% of the portfolio and ranks #3182 among its holdings. This is a return to the name: XTX Topco previously reported a position in NVCT as recently as Q3 2025.

XTX Topco first reported a position in NVCT in Q3 2025 and has held it in 2 quarters since. The position peaked at $89.5K in Q3 2025. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • XTX Topco held 10,066 shares of Nuvectis Pharma worth $77.8K as of Q1 2026.
  • Nuvectis Pharma was a new XTX Topco position in Q1 2026.
  • Nuvectis Pharma made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3182 holding.
  • XTX Topco first reported a position in Nuvectis Pharma in Q3 2025 and has held it in 2 quarters since.
  • XTX Topco's Nuvectis Pharma position peaked at $89.5K in Q3 2025.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.